Skip to main content

Table 1 Covariate adjusted interaction tests between tamoxifen treatment efficacy according to recurrence-free interval and different cell proliferation markers analyzed as continuous linear variables. Co-variables included age (≥ 65 versus < 65), grade (grade 3 versus grade 1–2), tumor size (T3–4 versus T1-T2), HER2 status (positive versus negative), and PgR status (positive versus negative)

From: Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

    Total follow-up Follow-up truncated at 6 yearsa
Variable Variable values N (events) p-value N (events) p-value
Mitotic count square root 0 to 11 515 (124) 0.16 515 (92) 0.09
Cyclin D1 (continuous) 0 to 100% 432 (105) 0.96  
Ki67 (continuous) 0 to 100 407 (99) 0.30
CCND1 probeset 1 log 2copy number ratio −2.43 to 3.36 450 (103) 0.21
CCND1 probeset 2 log2 copy number ratio −3.46 to 4.00 439 (102) 0.002
  1. aAnalysis performed for mitotic count only, since failure of proportional hazard assumption was observed